Últimas noticias sobre TFI International (NYSE:TFII) Bolsa

TFI International

TFI International Inc is a transportation and logistics company domiciled in Canada. The company organizes itself into four segments: package and courier, less-than-truckload, truckload, and logistics. The package and courier segment picks up, transports, and delivers items across North America. The less-than-truckload segment transports smaller loads. The truckload segment transports goods by flatbed trucks, containers, or a more specialized service. The company provides general logistics services through the logistics segment. TFI International derives the majority of its revenue domestically, followed by the United States.

TFI International Inc

News

PROC

Reported Friday, Procaps Faces Nasdaq Delisting Threat Due To Form 20-F Filing Delay, Seeks Hearing And Stay To Avoid Suspension

A prominent Wall Street analyst has reported a milestone for Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Full Self-Driving technology, completing an unassisted journey from Manhattan to Connecticut, marking a notable advancement in the <a href="https://www.benzinga.com/news/global/24/11/42028323/gary-black-defends-tesla-strategy-amid-clash-with-elon-musk-bulls-we-dont-trade-tesla-we-trim-when-the-price-goes-higher">company&#8217;s autonomous driving capabilities</a>.
What Happened: Pierre Ferragu, an analyst at New Street Research, shared his experience on X, formerly Twitter, stating, &#8220;Last night FSD got me out of deep into Manhattan and drove me back home to Connecticut. Got through a number of challenging and confusing situations with mastery. Not a single intervention. Robotaxi never felt that close ever before.&#8221;
For context, the drive from Manhattan to Connecticut spans approximately 94.7 miles and typically takes up to 1 hour and 45 minutes.
The successful navigation of complex urban environments represents a significant step forward for Tesla&#8217;s autonomous driving technology, particularly in challenging city conditions where s<a href="https://www.benzinga.com/news/24/09/41047267/safety-disaster-tesla-fsd-galaxies-away-from-being-anywhere-close-to-competition-says-bearish-analys">elf-driving systems typically face their greatest tests</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Last night FSD got me out of deep into Manhattan and drove me back home to Connecticut. Got through a number of challenging and confusing situation with mastery. Not a single intervention. Robotaxi never felt that close ever before…
&mdash; Pierre Ferragu (@p_ferragu) <a href="https://twitter.com/p_ferragu/status/1858138037009424474?ref_src=twsrc%5Etfw">November 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This development comes as Tesla continues to enhance its FSD technology amid growing competition in the autonomous vehicle sector from companies like Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)-backed Waymo, Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>). 
See Also: <a href="https://www.benzinga.com/24/11/42028342/blackwell-backfires-nvidias-ai-chips-struggle-with-server-overheating-impacting-meta-microsoft-and-musks-xai-data-centers">Nvidia&#8217;s Blackwell Chips Are Extra Toasty, Server Overheating Issues Impact Meta, Microsoft And Elon Musk&#8217;s xAI</a>
Why It Matters: The achievement is particularly notable given New York City&#8217;s demanding driving environment, known for its dense traffic, complex intersections, and unpredictable pedestrian movements.
Tesla&#8217;s autonomous driving progress comes at a crucial time as reports suggest a potential easing of federal regulations for self-driving vehicles, which could <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms">accelerate the company&#8217;s robotaxi ambitions</a>.
The stock has shown significant volatility over the past year, trading between $138.80 and $358.64, as investors weigh the company&#8217;s autonomous driving progress against market challenges, including changes to the federal EV tax credit structure.
Price Action: Tesla stock closed at $320.72 on Friday, gaining 3.07% for the day. In after-hours trading, the stock edged up 0.0062%. Year to date, Tesla's stock has risen by 29.10%, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42028523/cathie-wood-draws-reagan-era-parallels-as-elon-musk-takes-doge-helm-this-bull-market-has-just-begun-to-broaden-out">Cathie Wood Draws Reagan-Era Parallels As Elon Musk Takes DOGE Helm: &#8216;This Bull Market Has Just Begun To Broaden Out&#8217;</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Tech

BIDU

GOOG

GOOGL

MBLY

TSLA

Pierre Ferragu Says 'Robotaxi Never Felt That Close Ever Before' After Tesla Drove Through Challenging Roads With No Intervention

Elon Musk has predicted that AI will surpass doctors and lawyers after a study revealed OpenAI&#8217;s ChatGPT-4 outperformed medical professionals in diagnosing illnesses.
What Happened: A study <a href="https://www.nytimes.com/2024/11/17/health/chatgpt-ai-doctors-diagnosis.html">reported</a> by&nbsp;The New York Times&nbsp;revealed that AI achieved a 90% accuracy rate, compared to 76% for doctors using ChatGPT as a tool and 74% for doctors relying on traditional resources.
Following the publication of the report, Bindu Reddy, CEO of Abacus.AI, stated that an AI doctor with access to all lab reports would be able to diagnose problems and&nbsp;suggest remedies better than most&nbsp;human doctors.
See Also:&nbsp;<a href="https://www.benzinga.com/tech/24/11/41932289/ai-capabilities-plateauing-say-andreessen-horowitz-founders-echoing-concerns-of-openai-co-founder-ilya-sutskever?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AI Capabilities Plateauing, Say Andreessen Horowitz Founders, Echoing Concerns Of OpenAI Co-Founder Ilya Sutskever</a>
She added that the same would be true for lawyers and other knowledge-heavy professions.
Musk agreed with Reddy&#8217;s prediction, stating,&nbsp;&#8220;We can&nbsp;serve as a biological backstop&nbsp;for intelligence, as we are&nbsp;less brittle than silicon, and&nbsp;perhaps as a source of&nbsp;will.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">AI will soon beat doctors and lawyers by a large margin (and eventually all humans at almost everything). We can serve as a biological backstop for intelligence, as we are less brittle than silicon, and perhaps as a source of will.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1858305249783755206?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Last month, while speaking with Dr. Peter H. Diamandis, founder and executive chairman of the&nbsp;XPRIZE Foundation, Musk predicted that AI could <a href="https://www.benzinga.com/news/24/10/41618261/elon-musk-predicts-ai-will-match-human-capabilities-in-few-years-the-cup-is-80-full-maybe-90">reach human-level capabilities by 2029</a>.
Previously, the tech mogul has also said&nbsp;that the <a href="https://www.benzinga.com/news/24/06/39246781/elon-musk-thinks-humanoid-robots-will-one-day-exceed-human-population-from-nvidias-project-gr00t-to">number of humanoid robots</a> will one day exceed the human population.
&#8220;I think, long-term… the ratio of humanoid robots will be more than one-to-one. So, there probably might be two humanoid robots, or more, maybe 10, for every one human,&#8221; he earlier this year.
Earlier, Roman Yampolskiy, an AI safety researcher, also said that Musk&#8217;s company Neuralink, which aims to merge <a href="https://www.benzinga.com/news/24/06/39138007/elon-musks-neuralink-incredible-technology-can-make-humans-superhuman-says-ai-expert-but-warns-of-fu">human brains with Artificial General Intelligence</a> (AGI), could potentially make humans obsolete.
Image via Shutterstock
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42024288/consumer-tech-news-november-11-15-apple-plans-to-launch-an-ai-wall-tablet-meta-plans-to-introduce-ads-on-threads-more?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Consumer Tech News (November 11-15): Apple Plans To Launch An AI Wall Tablet, Meta Plans To Introduce Ads On Threads &amp; More</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Elon Musk Says AI Will Surpass Doctors, Lawyers After ChatGPT Tops Medical Diagnoses — Humans Becoming 'Biological' Backups

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has reached a major milestone by becoming the first company to deliver a new generation of super-powerful computer systems designed specifically for artificial intelligence.
What Happened: Michael Dell, the company&#8217;s CEO, announced on social media platform X that Dell is shipping its first liquid-cooled PowerEdge XE9712 systems to CoreWeave, a company that provides computing power for AI applications.
&#8220;The AI rocket just got a massive boost!&#8221; Michael Dell in his announcement, highlighted the significance of this achievement.
These new systems, developed in partnership with tech giant NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), are unlike traditional computers. They use special cooling technology that helps them handle the intense processing needed for advanced AI tasks. Think of it as the difference between a regular car engine and a Formula 1 racing engine – both are engines, but one is designed for much more powerful performance.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The 1st in the world <a href="https://twitter.com/nvidia?ref_src=twsrc%5Etfw">@nvidia</a> GB200 NVL72 server racks are now shipping. We are thrilled to deliver our liquid-cooled PowerEdge XE9712 to <a href="https://twitter.com/CoreWeave?ref_src=twsrc%5Etfw">@CoreWeave</a>. The AI rocket just got a massive boost! &#x1f916;&#x1f680;&#x1f91d; <a href="https://t.co/2QzlxbQE5f">pic.twitter.com/2QzlxbQE5f</a>
&mdash; Michael Dell (@MichaelDell) <a href="https://twitter.com/MichaelDell/status/1858306164775379268?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/24/11/42028954/peter-thiel-says-trumps-60-china-tariff-would-be-very-very-bad-for-beijing-heres-whats-at-stake">Peter Thiel Says Trump&#8217;s 60% China Tariff Would Be &#8216;Very, Very Bad&#8217; For Beijing, Here&#8217;s What&#8217;s At Stake</a>
Why It Matters: The system, called the GB200 NVL72, combines 72 powerful processing chips (GPUs) and 36 central computers (CPUs) working together as one unit. This allows it to run AI programs 30 times faster than previous systems, particularly when handling complex AI tasks like chatbots and image generation.
CoreWeave, the company receiving these first systems, specializes in providing high-powered computing services to businesses working with AI. They work closely with Nvidia, which designed the core technology inside these systems.
This development is particularly important as companies worldwide are racing to build and access more powerful AI computing systems. Industry experts predict high demand for these systems, with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39168191/nvidia-maintains-lead-as-key-ai-beneficiary-analyst-boosts-estimates-after-taiwan-e">estimates suggesting 20,000 to 25,000 similar systems could be shipped in 2025</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42028523/cathie-wood-draws-reagan-era-parallels-as-elon-musk-takes-doge-helm-this-bull-market-has-just-begun-to-broaden-out">Cathie Wood Draws Reagan-Era Parallels As Elon Musk Takes DOGE Helm: &#8216;This Bull Market Has Just Begun To Broaden Out&#8217;</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

DELL

NVDA

Dell Ships First 72-Nvidia GPU Monster: 'AI Rocket Just Got A Massive Boost,' Says CEO

<ul>
<li>Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life</li>
<li>New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of Patients Guideline Eligible for Septal Reduction Therapy</li>
<li>Analyses of Real-World Data Reveal Cost of Care Differences in HCM&nbsp;Across Gender, Age and Race/Ethnicity</li>
</ul>

CYTK

Reported Saturday, Cytokinetics Unveils New Data On Aficamten And Hypertrophic Cardiomyopathy At AHA Scientific Sessions 2024

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
"These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia," said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. "As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating its potential to reduce the risk of adverse heart failure outcomes across the spectrum of these very high-risk patients failing guideline-directed medical therapy."

Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue
-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases
-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV)

ACET

Reported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024

<ul>
<li>In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations</li>
<li>Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation</li>
<li>Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies</li>
</ul>

Reported Saturday, Eli Lilly's Tirzepatide Cuts Heart Failure Risk By 38% In Adults With Heart Failure With Preserved Ejection Fraction (HFpEF) And Obesity

On Sunday, President-elect Donald Trump picked pro-Starlink Republican Brendan Carr as chairman of the Federal Communications Commission, or FCC.
What Happened: &#8220;Commissioner Carr is a warrior for Free Speech, and has fought against the regulatory Lawfare that has stifled Americans&#8217; Freedoms, and held back our Economy. He will end the regulatory onslaught that has been crippling America&#8217;s Job Creators and Innovators, and ensure that the FCC delivers for rural America,&#8221; Trump wrote in his statement. 
Carr, a vocal critic of big tech companies, wrote on X that he is &#8220;humbled and noted&#8221; to take on the role. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you, President Trump! I am humbled and honored to serve as Chairman of the FCC. Now we get to work. &#x1f1fa;&#x1f1f8; <a href="https://t.co/MPyL2d38kT">pic.twitter.com/MPyL2d38kT</a>
&mdash; Brendan Carr (@BrendanCarrFCC) <a href="https://twitter.com/BrendanCarrFCC/status/1858311955024400868?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Carr wrote last week that &#8220;Facebook, Google, Apple, Microsoft, and others have played central roles in the censorship cartel,&#8221; adding that they must be &#8220;dismantled.&#8221;
Carr currently serves as the senior Republican on the FCC. The FCC is an independent U.S. government agency overseen by Congress and regulates interstate and international communications by radio, television, wire, satellite, and cable in all 50 states, the District of Columbia, and U.S. territories. 
Jessica Rosenworcel currently serves as the Chairperson of the Commission. 
Why It Matters: Carr is a strong supporter of Musk&#8217;s Starlink. He staunchly <a href="https://www.benzinga.com/news/24/09/40672229/starlink-ineligible-for-nearly-900m-in-subsidies-says-fcc-spacex-ceo-elon-musk-says-it-is-flat-out-l">opposed the FCC&#8217;s decision not to offer nearly $900 million in subsidies to Starlink</a> alleging that the FCC had added itself to the growing list of administrative agencies taking action against Musk's businesses following the billionaire's acquisition of Twitter (now X) on the instructions of President Joe Biden. 
Carr also said on Monday that the FCC will stop promoting Diversity, Equity, Inclusion, and Accessibility (DEI) initiatives.
&#8220;The FCC's most recent budget request said that promoting DEI was the agency's second-highest strategic goal. Starting next year, the FCC will end its promotion of DEI,&#8221; he wrote on X. 
Musk is also staunchly <a href="https://www.benzinga.com/news/24/04/38064076/mark-cuban-vows-to-defend-deis-positive-impact-on-business-because-they-are-opposite-of-elon-musk-an">opposed to DEI programs</a>, terming them &#8220;racist.&#8221; Musk regards preference for certain sections of the population in DEI programs as &#8220;racism&#8221; towards the majority white population. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42025362/former-uber-executive-and-3-congressmen-contenders-for-trumps-transportation-chief-role-report">Former Uber Executive And 3 Congressmen Contenders For Trump&#8217;s Transportation Chief Role: Report</a></li>
</ul>
Photo courtesy: Gage Skidmore via Flickr

SPACE

Trump Names Pro-Starlink FCC Commissioner Brendan Carr As Chairperson, Says He Will 'End The Regulatory Onslaught'

<ul>
<li>Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis</li>
<li>Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patients</li>
<li>Consistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baseline</li>
<li>Persistently deep levels of serum TTR reductions following a single infusion remain virtually unchanged after two or more years of follow-up in over 25 patients</li>
<li>Favorable safety and tolerability profile observed</li>
<li>ATTR-CM data presented at the 2024 AHA Scientific Sessions and published in the New England Journal of Medicine</li>
</ul>

NTLA

Reported Saturday, Intellia Announced Initial Phase 1 Data Suggesting Nexiguran Ziclumeran, An In Vivo CRISPR/Cas9 Gene Editing Therapy, May Benefit ATTR Amyloidosis Progression

BMRN

Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024

BioCryst Pharmaceuticals, Inc.&nbsp;(Nasdaq:&nbsp;BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO&#xAE;&nbsp;(berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
"The positive HSE recommendation of ORLADEYO&nbsp;broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Ireland," said Charlie Gayer, chief commercial officer of BioCryst.
The HSE decision in Ireland follows the European Commission marketing authorization of ORLADEYO in April 2021. To date, ORLADEYO is licensed in 44 countries.

Government

Regulations

BCRX

BioCryst's ORLADEYO Gets Ireland's Approval: Expanding Access to Once-Daily HAE Therapy

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation

Reported Saturday, Boston Scientific's WATCHMAN FLX Device Shows Superior Bleeding Risk Reduction Compared To Oral Anticoagulants After Cardiac Ablation In OPTION Clinical Trial

<ul>
<li>New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models</li>
<li>Engineered TIM4-expressing macrophages correct defective&nbsp;efferocytosis in MASH, demonstrating potent anti-fibrotic activity&nbsp;</li>
</ul>

CARM

Reported Sunday, Carisma Therapeutics Unveils Preclinical Data On Engineered Macrophages For Liver Fibrosis Treatment At AASLD The Liver Meeting 2024

<ul>
<li>Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months&nbsp;</li>
<li>At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −</li>
<li>Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −</li>
<li>Encouraging Safety and Tolerability Observed −</li>
<li>Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –</li>
</ul>

ALNY

Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose

"The preclinical data presented at ACR Convergence underscore the exceptional potential of our targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4, which are critical targets in inflammatory and autoimmune diseases, and support continued advancement of these drug candidates into clinical studies," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "These programs showcase the capability of Nurix's DELigase platform to generate potent best-in-class degrader drug candidates with the potential to deliver superior efficacy in several inflammatory diseases."

NRIX

Reported Sunday, Nurix Therapeutics Showcased Preclinical Data On NX-5948 And GS-6791 From Autoimmune And Inflammatory Disease Programs At ACR Convergence 2024

<ul>
<li>ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer</li>
<li>ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy</li>
<li>VENTANA FOLR1 (FOLR1-2.1)&nbsp;RxDx Assay, the companion diagnostic to identify ovarian cancer patients eligible for ELAHERE, also receives CE Mark</li>
</ul>

ABBV

AbbVie Secures European Commission Approval For ELAHERE, First Novel Therapy For Platinum-Resistant Ovarian Cancer

<ul>
<li>The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.</li>
<li>The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE. &nbsp;</li>
<li>This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.</li>
</ul>

RHHBF

RHHBY

Roche Secures CE Mark For VENTANA FOLR1 RxDx Assay, The First IHC Diagnostic For Identifying Epithelial Ovarian Cancer Patients Eligible For ELAHERE

<ul>
<li>Revere Medical Enters into Agreement to Acquire CareMax's Management Services Organization</li>
<li>Agreement in Principle Reached with "Stalking Horse" for Core Centers' Assets</li>
<li>Sale Transactions to be Implemented Through an Expedited Prearranged Chapter 11 Plan Supported by 100% of CareMax's Secured Lenders</li>
<li>CareMax Secures $30.5 Million in Debtor in Possession Financing to Support Operations and Continuing Provision of Healthcare Services Throughout Restructuring Process</li>
</ul>

CMAX

Reported Sunday, CareMax Enters Prearranged Chapter 11, Reaches Deal To Sell MSO And Core Centers' Assets, Secures $30.5M DIP Financing

Reported Sunday, Apollo Opens Seoul Office Amid APAC Expansion, Taps Samsung Securities Veteran Jay Hyun Lee As Head Of Korea

TFI International (TSE:TFII) has released an update. TFI International has announced the retirement of Neil Manning, an independent director, after...

TFI International Announces Director Retirement

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on A. O. Smith Corporation (AOS – Research Report), TFI Intern...

Analysts Offer Insights on Industrial Goods Companies: A. O. Smith Corporation (AOS), TFI International (TFII) and Herc Holdings (HRI)

Stifel downgraded TFI International (TFII) to Hold from Buy with a price target of $142, down from $158. The company's operating environment and ne...

TFI International downgraded to Hold from Buy at Stifel

Veritas upgraded TFI International (TFII) to Buy from Reduce with a price target of $147, down from $155. Published first on TheFly – the ultimate ...

TFI International upgraded to Buy from Reduce at Veritas

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on GE Aerospace (GE – Research Report), TFI International (TFI...

Analysts Offer Insights on Industrial Goods Companies: GE Aerospace (GE), TFI International (TFII) and Robert Half (RHI)

National Bank lowered the firm's price target on TFI International (TFII) to C$198 from C$209 and keeps a Sector Perform rating on the shares follo...

TFI International price target lowered to C$198 from C$209 at National Bank

In a report released today, Fadi Chamoun from BMO Capital maintained a Hold rating on TFI International (TFII – Research Report), with a price targ...

TFI International (TFII) Gets a Hold from BMO Capital

TFI International (TSE:TFII) has released an update. TFI International has announced the renewal of its normal course issuer bid, allowing the comp...

TFI International Renews Share Buyback Plan

TFI International (TFII) announced that the Toronto Stock Exchange has approved the renewal of TFI International's normal course issuer bid, or NCI...

TFI International renews normal course issuer bid

Citi raised the firm's price target on TFI International (TFII) to $170 from $158 and keeps a Buy rating on the shares. The firm says sentiment app...

Comments

TFI International

Noticias

Últimas noticias sobre TFI International (NYSE:TFII) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL